123 related articles for article (PubMed ID: 29575357)
1. RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Kaya G; Saxer-Sekulic N; Kaya A; Sorg O; Boespflug A; Thomas L; Saurat JH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1368-1372. PubMed ID: 29575357
[TBL] [Abstract][Full Text] [Related]
2. Aryl Hydrocarbon Receptor Activation in Acne Vulgaris Skin: A Case Series from the Region of Naples, Italy.
Fabbrocini G; Kaya G; Caseiro Silverio P; De Vita V; Kaya A; Fontao F; Sorg O; Saurat JH
Dermatology; 2015; 231(4):334-8. PubMed ID: 26440531
[TBL] [Abstract][Full Text] [Related]
3. Chloracne: a case series on cutaneous expression of CYP1A1 as diagnostic biomarker.
Chessa MA; La Placa M; Patrizi A; Virdi A; Misciali C; Fedrizzi G; Filippi F; Saurat JH; Sorg O; Fontao F; Kaya G; Neri I
Clin Exp Dermatol; 2021 Jul; 46(5):896-900. PubMed ID: 33638914
[TBL] [Abstract][Full Text] [Related]
4. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
5. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
6. Expression of AhR, CYP1A1, GSTA1, c-fos and TGF-alpha in skin lesions from dioxin-exposed humans with chloracne.
Tang NJ; Liu J; Coenraads PJ; Dong L; Zhao LJ; Ma SW; Chen X; Zhang CM; Ma XM; Wei WG; Zhang P; Bai ZP
Toxicol Lett; 2008 Apr; 177(3):182-7. PubMed ID: 18329192
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events.
Hawerkamp HC; Kislat A; Gerber PA; Pollet M; Rolfes KM; Soshilov AA; Denison MS; Momin AA; Arold ST; Datsi A; Braun SA; Oláh P; Lacouture ME; Krutmann J; Haarmann-Stemmann T; Homey B; Meller S
Allergy; 2019 Dec; 74(12):2437-2448. PubMed ID: 31269229
[TBL] [Abstract][Full Text] [Related]
8. Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
Ueno M; Namiki T; Inui K; Hanafusa T; Miura K; Yokozeki H
Int J Dermatol; 2017 Aug; 56(8):e163-e165. PubMed ID: 28244062
[No Abstract] [Full Text] [Related]
9. Activation of Nrf2 in keratinocytes causes chloracne (MADISH)-like skin disease in mice.
Schäfer M; Willrodt AH; Kurinna S; Link AS; Farwanah H; Geusau A; Gruber F; Sorg O; Huebner AJ; Roop DR; Sandhoff K; Saurat JH; Tschachler E; Schneider MR; Langbein L; Bloch W; Beer HD; Werner S
EMBO Mol Med; 2014 Apr; 6(4):442-57. PubMed ID: 24503019
[TBL] [Abstract][Full Text] [Related]
10. Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib.
Ansai O; Fujikawa H; Shimomura Y; Abe R
J Dermatol; 2017 Mar; 44(3):e15-e16. PubMed ID: 27511106
[No Abstract] [Full Text] [Related]
11. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
13. Chloracne: still cause for concern.
Passarini B; Infusino SD; Kasapi E
Dermatology; 2010 Aug; 221(1):63-70. PubMed ID: 20516651
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
15. Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits.
Hao J; Fan W; Li Y; Tang R; Tian C; Yang Q; Zhu T; Diao C; Hu S; Chen M; Guo P; Long Q; Zhang C; Qin G; Yu W; Chen M; Li L; Qin L; Wang J; Zhang X; Ren Y; Zhou P; Zou L; Jiang K; Guo W; Deng W
J Exp Clin Cancer Res; 2019 Feb; 38(1):48. PubMed ID: 30717768
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous Adnexal Cysts Revisited: What We Know and What We Think We Know.
Kaya G; Saurat JH
Dermatopathology (Basel); 2018; 5(2):79-85. PubMed ID: 29998103
[TBL] [Abstract][Full Text] [Related]
17. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
Hui Ong EL; Sinha R; Jmor S; Fearfield L
Am J Dermatopathol; 2019 Mar; 41(3):214-217. PubMed ID: 30601209
[TBL] [Abstract][Full Text] [Related]
18. Toward elucidation of dioxin-mediated chloracne and Ah receptor functions.
Bock KW
Biochem Pharmacol; 2016 Jul; 112():1-5. PubMed ID: 26801687
[TBL] [Abstract][Full Text] [Related]
19. Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.
Eser Öztürk H; Süllü Y
Turk J Ophthalmol; 2020 Mar; 50(1):50-52. PubMed ID: 32167264
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
